New Psychoactive Substances: A Guide for Pharmacists
A. Gürçü1, C. Bond1, G. Hawksworth1, J. Lawrence1 and L. Martini2

1Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, University of Hertfordshire, UK.
2Science and Research Board, Royal Pharmaceutical Society, UK.

What are New Psychoactive Substances?

- The UK Psychoactive Substances Act (PSA) 2016 describes compounds commonly known as new psychoactive substances (NPS) as ‘psychoactive substances’ that are ‘capable of producing a psychoactive effect’. [1] The term ‘new’ does not necessarily mean newly invented/synthesised but rather recently made available for recreational use [2] and includes faked or existing pharmaceuticals such as over-the-counter (OTC) medicines (codeine-based medicines, dextromethorphan, diphenhydramine hydrochloride, pseudoephedrine, ephedrine, laxatives, benzodiazepines) or prescription only medicines (POMs) (opioids, benzodiazepines, stimulants e.g. methylphenidate) used in novel ways and in new formulations [3-5]. The term ‘new’ has therefore been included in the UK PSA 2016 definition, possibly to broaden the description of these substances.

- Until recently, when NPS came onto the UK market, they were by default legal purely because they had not yet been banned. It is still possible that an NPS can be legal in one country and illegal in another. In the UK, NPS are now controlled under the UK PSA 2016.

- In December 2016, the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) reported more than 620 NPS at a European level and estimated the emergence of one new NPS onto the EU market every week [6]. At a global level, the United Nations Office on Drugs and Crime (UNODC) has reported more than 740 NPS [7].

- To enable their identification, NPS are currently accepted according to their chemical classes, chemical structures, or pharmacological classes. The main groups based on NPS effects include: NMDA Agonists; Dissociatives; Hallucinogens; Stimulants; Synthetic Cannabinoid Receptor Agonists (SCRA); New Synthetic Opioids (see UNODC report). For their legal status based on the Misuse of Drugs Act 1971 or the UK PSA 2016 (see The Drug Whistle [6-8].

What do they look like? What to watch out for?

Various NPS products: (a) A nitrous oxide canister found in the street, (b) NPS sold on the surface web as a branded product ‘High Beam’, (c) to (g) research chemical powders with a safety sheet type label, (h) cognitive enhancer supplements ‘insuranc’ or (j) pharmaceutical tablets ‘psykylarant’

- NPS are sold online, disguised on the surface web, openly on the deep net of the dark web, in the illicit drug market as NPS or as illicit drugs (e.g. heroin or ecstasy) covertly containing NPS. They are sold purported to be ‘high quality potent pure’; incense, research chemicals, legal highs, herbal highs, designer drugs, food supplements, performance and image enhancers or as branded products (e.g. Pink Panthers, Burnbury) [9-10]. They can also be sold under their claimed chemical name e.g. (1-5-fluoropentyl)-1-(1-naphthyl) indole, as acronyms e.g. AM-2201, or active pharmaceutical ingredients e.g. methylphenidate [9-10].

- The NPS content in NPS products may be claimed on the label but information on labels cannot be relied upon. NPS products may contain unclaimed NPS (not listed on the label). Illicit drugs, POMs, controlled drug precursors, or other drugs e.g. benzodiazepines, lidocaine, procaine, diltiazem, phenoxybenzamine, bupropion, caffeine, creatine, glutamate, L-tyrosine, lactose, microcrystalline cellulose, nicotineacid, trace elements, or synthesis by-products [9-11].

- NPS are sold in different formulations (tablets, capsules, pellets, powders, herbal, herbal extracts, seeds or e-liquids). They can also be sprayed on herbs. NPS are taken via various routes and modes: orally, sublingually, buccally, transdermally parenterally, rectally, intranasally (e.g. snorted), via inhalation, vapor or smoking (also through a spray or vapourisation) [12]. Various words or phrases are used on the street to describe administration including: keying (drug is spooned onto a key then inhaled) or slaming (men intravenously injecting psychoactives in a sexual context to improve mood and induce sexual disinhibition [13]) or snorting (drugs are ground and wrapped in a cigarette paper then swallowed) or plugging (drug is rectally administered) or vaporisation [9].

- Injecting (NPS as with injecting traditional drugs of abuse) introduces health problems such as blood-borne infections (HBV, hepatitis C virus, hepatitis B virus), sexually transmitted infections, infections at the site of injections, skin necrosis, abscesses and development of aspects of addiction such as compulsive behaviour, sharing needles, craving, and withdrawal symptoms [1-6].

- NPS use is prevalent among all age ranges. They are popular among students, professionals, unemployed, party goers, prisoners, high-risk injecting drug users, patients on opioid substitution therapy [15, 16]. Lesbians, gay, bisexual and transgender individuals, men who have sex with men (MSM), heroin users, clubbers and the homeless population [17].

- In addition to mental and physical withdrawal symptoms, NPS are also associated with a plethora of mental and physical toxic effects including neurotoxic, psychiatric, metabolic and cardiovascular effects. Sexually transmitted diseases and outbreaks of blood-borne infections are on the rise because of chemsex (NPS facilitated sex among MSM) [2].

Recommendations for Pharmacists

- Pharmacists need to be aware of the changes in the drug scene and the implications this may have on their day-to-day practice; the section below provides ‘ Useful Resources’ for the education of pharmacists around the harms and clinical management of NPS.

- Many pharmacists provide harm reduction services that can also be relevant to NPS users such as needle and syringe exchange programmes, advice on safer injecting techniques, injecting hygiene, alternatives to injecting and vein care.

- Pharmacists should also advise patients attempting to purchase medicines or supplements online on how to identify legitimate online pharmacies (see CQC website for more information).

- Pharmacists should not supply medicines to anyone if they believe them to be intoxicated, the signs and symptoms of which include psychosis, seizures, agitation, violence, aggression, cardiovascular symptoms (e.g. chest pain), and gastrointestinal symptoms (e.g. nausea, vomiting). However, the range of symptoms presented may vary depending upon a variety of factors such as poly-usage.

- A briefing on SCRA has recommended healthcare professionals call an ambulance if an overdose is suspected or dial 999 if in doubt of what action to take [18].

- Pharmacists should access the use of NPS, performance and image enhancing drugs, or herbal/dietary supplements during their consultations with patients such as medicines review drugs, use history taking and regular follow-ups, and educate and refer appropriately to psychosocial, physical, mental, sexual health or addiction services (e.g. CGL (Change, Grow, Live), Addiction).

- Pharmacists should assess the degree of problem use e.g. diverted use of OTC medicines or POMs in addition to NPS use, risky behaviours e.g. injecting family history of substance use. NPS supply through family members or friends, psychiatric co-morbidities, need for additional strong opioids, for chronic pain management and drug-drug interactions.

- During drug history taking, pharmacists should ask about the name of the substance thought to be consumed, co-consumed substances, alcohol and tobacco smoking, route of administration, frequency of intake and perceived amounts (the potency and strength of the substance may not be known).

- Based on the UK guidelines on the clinical management of drug misuse and dependence, it is recommended to encourage smoking cessation in people smoking illicit substances as there has been shown that these individuals are most likely to adopt risky behaviours of substance use e.g. injecting. It is also recommended to encourage hepatitis B vaccination in individuals who are likely to progress to injecting [19].

- It is recommended to report adverse effects related to NPS to the Public Health England (PHE) Report Illicit Drugs Reactions (IDR) system.

- Pharmacists should be aware of NPS classes associated with high-risk use. These include: (a) SCRA; (b) synthetic cannabinoids (e.g. naphthol (4-MMC), 1-MMC, 4-MEC, pentedrone, and pyrrolone derivatives such as MDPV or alpha-PVP); (c) new synthetic opioids (e.g. AH-7921, MT-45 and U-47700) and (d) benzodiazepines (counterfeit alprazolam, flurazepam, diazepam, phenazepam and etizolam).
Useful Resources

Useful resources can be found in the following links:

1. General information on NPS:
   - EMCDDA publications: Public Health England guidance on NPS; Scottish Drugs Forum (SDF) Weddings and the Weddings annual report 2016; EU MADNESS Project Fact Sheets; RPS Guide on NPS.

2. Clinical guidance for healthcare professionals:
   - Underlining the patterns of use, motives, and harms of New Psychoactive Substances in Scotland (2016).
   - CPP educational module: Substance use and misuse (2017); WCPE: educational module: Substance Misuse (2017).

3. Databases for healthcare professionals for reporting ADRs and obtaining peer information on treatment of poisoning:

4. Referral:

References


Acknowledgements

This work has been initiated on behalf of the RPS Science and Research Board by Amira Garguis, Christine Bond, Gill Hawkesworth, Jayne Lawrence and Luigi Gina Martin. All authors would like to acknowledge contributions from the Psychopharmacology Drug Misuse and Novel Psychoactive Substances Research Unit, University of Hertfordshire (lead Prof. F. Scifiano).

Further questions can be directed to the RPS Support: support@nhsChoices.com

Publication date: April 2018
Review date: April 2019